IKT - NASDAQ
Inhibikase Therapeutics, Inc.
$1.70
-0.88%Inhibikase Therapeutics, Inc., a clinical stage pharmaceutical company, develops therapeutics for Parkinson's Disease (PD) and related disorders that arise inside and outside of the brain. The company's product candidates include IkT-148009, a small molecule Abelson tyrosine kinase inhibitor for use in the treatment of PD, as well as gastrointestinal complications that arise as early symptoms of PD, such as swallowing, dysphagia, neurogenic constipation, and multiple system atrophy; and IkT-001Pro, a prodrug of the anti-cancer agent Imatinib that is in preclinical development to minimize gastrointestinal side effects and for the treatment of blood and stomach cancers. It is also involved in developing various research programs for other neurological diseases. The company has research and development collaborations with The Johns Hopkins University, Arizona State University, and Michigan State University, as well as Louisiana State University. Inhibikase Therapeutics, Inc. was founded in 2008 and is headquartered in Atlanta, Georgia.
At a Glance
Live Snapshotikt
Cash and Cash Equivalents
Last Annual Value
139.22M
3-Year CAGR
169%
5-Year CAGR
58%
10-Year CAGR
155%
Inhibikase Therapeutics, Inc. Competitors Analysis of Cash and Cash Equivalents
| Company | Cash and Cash Equivalents | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
Inhibikase Therapeutics, Inc. NASDAQ:IKT | 139.22M | 147.7% | 27.9% | 154.9% | |
 Atossa Therapeutics, Inc. NASDAQ:ATOS | 41.30M | -22.4% | -21.3% | 29.9% | |
 Agenus Inc. NASDAQ:AGEN | 3.00M | -66.0% | -60.0% | -27.7% | |
 Turn Therapeutics Inc. NASDAQ:TTRX | 5.08M | 62.6% | N/A | N/A | |
 Armata Pharmaceuticals, Inc. AMEX:ARMP | 8.69M | -13.7% | -3.3% | 4.3% | |
 Opus Genetics, Inc. NASDAQ:IRD | 45.09M | -3.7% | 12.9% | N/A | |
 Nautilus Biotechnology, Inc. NASDAQ:NAUT | 12.39M | -13.9% | -41.8% | N/A | |
 TScan Therapeutics, Inc. NASDAQ:TCRX | 152.41M | 4.6% | -1.1% | N/A | |
 VistaGen Therapeutics, Inc. NASDAQ:VTGN | 67.13M | 59.2% | -8.2% | 65.8% | |
 Coya Therapeutics, Inc. NASDAQ:COYA | 46.82M | 12.8% | 60.9% | N/A | |
 Ovid Therapeutics Inc. NASDAQ:OVID | 13.15M | -21.4% | -41.2% | -12.8% |
Inhibikase Therapeutics, Inc. Fair Value Envelope
Related Guides
Continue your IKT research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.